Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-38319 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) | Title of each class: | ...

Quanterix Corporation (NASDAQ:QTRX) Q1 2020 Earnings Conference Call May 5, 2020 4:30 PM ET Company Participants Amol Chaubal - Chief Financial Officer Kevin Hrusovsky - Chief Executive Officer, President & Chairman Conference Call Participants Sung Ji Nam - BTIG Puneet Souda - SVB Leerink Max Masucci - Canaccord Genuity Ryan Blicker - Cowen and Company Operator Good afternoon ladies and gentlemen and welcome to the Quanterix Corporation Quarter One 2020 Earnings Call. At this time, all lines are -- all par ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001‑38319 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 20‑8957988 (Sta ...

| --- | --- | --- | --- | --- | --- | |--------------------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | Q1 2020 Earnings Call | | | | | | | Kevin Hrusovsky & Amol Chaubal | | | | | | Forward-Looking Statements & Non-GAAP Financial Measures This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and sim ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001‑38319 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware (State or other jurisd ...

| --- | --- | --- | --- | --- | |-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Forward-Looking Statements & Non-GAAP Financial Measures This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circu ...

Quanterix Corporation (NASDAQ:QTRX) Q4 2019 Earnings Conference Call March 9, 2020 4:30 PM ET Company Participants Amol Chaubal - CFO Kevin Hrusovsky - CEO, President and Chairman Conference Call Participants Puneet Souda - SVB Leerink Sung Ji Nam - BTIG Tycho Peterson - JPMorgan Max Masucci - Canaccord Genuity Operator Ladies and gentlemen, thank you for standing by, and welcome to the Quanterix Corporation Q4 and Full-Year 2019 Earnings Call. [Operator Instructions] I would now like to hand the conference ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 For the transition period from to . Commission File Number: 001‑38319 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 20‑8957988 (St ...

财务数据关键指标变化：收入增长 - 公司总营收同比增长56.6%至1353.6万美元，其中产品收入增长68.8%至877.6万美元[126][127] - 公司总营收同比增长60.1%，从1616.4万美元增至2587.2万美元[135][136] - 产品收入增长84.2%，从994.5万美元增至1832.2万美元，其中仪器销售610万美元、耗材及其他产品1220万美元[135][137] - 服务及其他收入增长32.9%，从568.2万美元增至755万美元[135][137] - 耗材销售收入从340万美元增长至610万美元，增幅达79.4%[127] - 仪器销售额从180万美元增至270万美元，同比增长50%[127] - 服务收入增长50%至476万美元，主要因加速器实验室使用率提升[126][129] - 合作与许可收入降幅100%，从53.7万美元降至零[135][137] 财务数据关键指标变化：利润和亏损 - 运营亏损扩大43.8%至1051.4万美元，主要因行政费用增长77.2%[126][133] - 运营亏损从1447.5万美元扩大至1987.3万美元，增幅37.3%[135] - 毛利润增长81.0%至1293.6万美元[135][139] - 毛利率从46%提升至51.2%，主要因生产成本下降[126][131] - 销售成本占营收比例从55.8%降至50.0%[135][139] 成本和费用 - 研发费用增长8.4%至401.6万美元，用于SP-X和HD-X仪器开发[126][132] - 研发费用增长7.1%至786.8万美元，主要用于耗材和SP-X仪器开发[140] - 销售及行政费用增长74.8%至2494.1万美元，主因组织扩张与上市公司成本增加[141] 现金和融资活动 - 现金及现金等价物为7200万美元，累计亏损达1.954亿美元[125] - 通过ATM发行计划售出218.6万股普通股，获得净融资4800万美元[145] - 融资活动现金流入5030万美元，主要来自2019年第二季度ATM发行[165] - 公司现金储备预计可支撑运营至2020年第三季度[168] - 公司S-3注册声明剩余1.5亿美元证券发行额度[169] 收购活动 - 公司以2250万美元收购Uman，其中现金1600万美元加股票650万美元[124] - 此前以320万美元现金收购Aushon Biosystems，另支付80万美元后续款项[122] 债务情况 - 赫拉克勒斯贷款协议未偿还本金781.3万美元，其中2021年到期781.3万美元[156] - 贷款协议修订将付息期延至2021年7月，到期日延至2021年10月[170] 经营活动现金流 - 2019年上半年经营活动净现金流出1280万美元，净亏损2000万美元[160] - 2018年上半年经营活动净现金流出1400万美元，净亏损1450万美元[161] - 非现金支出包括290万美元股权激励费用和100万美元折旧摊销[160] - 营运资本变动导致现金流出330万美元，主因其他非流动负债增加940万美元[160] - 应收账款增加230万美元，存货增加290万美元，应付账款减少160万美元[160] 投资活动现金流 - 投资活动现金流出980万美元（2019年）vs 370万美元（2018年）[163][164]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-38319 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 20-8957988 (State or other jurisd ...